PANG Pangaea Oncology, S.A.

1.612USD1.470 EUR · BME0.00%Mkt Cap: 57.95M USDP/E: —

Pangaea Oncology, S.A., a precision oncology company, provides a range of services to cancer patients in Spain and the rest of European Union countries. The company offers molecular diagnostics, including mutation analys…

Key Statistics

Company
Market Cap57.95M USD
Enterprise Value61.45M USD
Revenue (TTM)16.45M USD
Gross Profit15.82M USD
Net Income (TTM)-3.94M USD
Revenue/Share0.46 USD
Last Price1.612 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees199
CountryES
SectorHealthcare
IndustryDiagnostics & Research
ISINES0105221008
Valuation
P/E (Trailing)—
P/E (Forward)Infinity
PEG—
EV/EBITDA-15.38
EV/Revenue3.74
P/S3.52
P/B3.01
EPS (TTM)-0.16 USD
EPS (Forward)0.00 USD
52W Range
1.56813% of range1.919
52W High1.919 USD
52W Low1.568 USD
Profitability
Gross Margin99.28%
Oper. Margin-27.87%
EBITDA Margin-24.29%
Profit Margin-24.76%
ROE-16.88%
ROA-11.20%
ROIC-13.01%
ROCE-14.64%
Growth
Revenue Growth6.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-2.76M USD
CapEx (TTM)518.22K USD
FCF Margin1.32%
FCF Yield0.37%
Net Debt2.72M USD
Net Debt/EBITDA-0.68
Net Debt/FCF12.54
Balance Sheet
Debt/Equity0.27
Current Ratio1.58
Quick Ratio1.44
Book Value/Sh0.54 USD
Cash/Share0.05 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.35.94M
Float30.89M
Insiders69.26%
Institutions0.34%
Technical
SMA 501.589 (+1.5%)
SMA 2001.714 (-5.9%)
Beta0.11
S&P 52W Chg12.00%
Avg Vol (30d)1.04K
Avg Vol (10d)0
Technical Indicators
RSI (14)52.4
MACD0.0020
MACD Signal0.0013
MACD Hist.+0.0007
BB Upper1.630 USD
BB Middle1.610 USD
BB Lower1.590 USD
BB Width2.44%
ATR (14)0.0058 USD
Vol Ratio (20d)0.00x

About Pangaea Oncology (BME: PANG)

›

Pangaea Oncology (BME: PANG) is listed on the Bolsa de Madrid, where its shares trade in EUR. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 199 employees.

The shares were at 1.470 EUR on 18 November 2026, down 13.5% over 52 weeks. Its 52-week range is 1.430 EUR to 1.750 EUR: the price is 16.0% below the high and 2.8% above the low.

Its market capitalisation is 52.84M EUR.

Pangaea Oncology reports return on equity of -16.9%, an operating margin of -27.9% and revenue up 6.6% year over year.

Its debt exceeds its cash by 2.48M EUR, a debt-to-equity ratio of 0.27. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.